Apoptosis-induced translocation of centromere protein F in its corresponding autoantibody production in hepatocellular carcinoma

References

• Henley SJ, Ward EM, Scott S, Ma J, Anderson RN, Firth AU, Thomas CC, Islami F, Weir HK, Lewis DR, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. 2020;126:2225–15. doi:10.1002/cncr.32802.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. doi:10.3322/caac.21551.
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastro Hepat. 2019;16:589–604. doi:10.1038/s41575-019-0186-y.
   PubMed Web of Science ®Google Scholar
• Honsová E. Histopathological differential diagnosis of primary liver tumors. Rozhl Chir. 2014;93:170–175.
   PubMedGoogle Scholar
• Zaenker P, Gray ES, Ziman MR. Autoantibody production in cancer–the humoral immune response toward autologous antigens in cancer patients. Autoimmun Rev. 2016;15:477–483. doi:10.1016/j.autrev.2016.01.017.
   PubMed Web of Science ®Google Scholar
• Hong Y, Huang J. Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma. World J Hepatol. 2015;7:1581–1585. doi:10.4254/wjh.v7.i11.1581.
   PubMed Web of Science ®Google Scholar
• Koziol JA, Imai H, Dai L, Zhang J, Tan EM. Early detection of hepatocellular carcinoma using autoantibody profiles from a panel of tumor-associated antigens. Cancer Immunol Immunother. 2018;67:835–841. doi:10.1007/s00262-018-2135-y.
   PubMed Web of Science ®Google Scholar
• Hong Y, Long J, Li H, Chen S, Liu Q, Zhang B, He X, Wang Y, Li H, Li Y, et al. An analysis of immunoreactive signatures in early stage hepatocellular carcinoma. EBioMedicine. 2015;2:438–446. doi:10.1016/j.ebiom.2015.03.010.
   PubMed Web of Science ®Google Scholar
• Varis A, Salmela AL, Kallio MJ. Cenp-F (mitosin) is more than a mitotic marker. Chromosoma. 2006;115:288–295. doi:10.1007/s00412-005-0046-0.
   PubMed Web of Science ®Google Scholar
• Hussein D, Taylor SS. Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis. J Cell Sci. 2002;115:3403–3414. doi:10.1242/jcs.115.17.3403.
   PubMed Web of Science ®Google Scholar
• Rattner JB, Rao A, Fritzler MJ, Valencia DW, Yen TJ. CENP-F is a .ca 400 kDa kinetochore protein that exhibits a cell-cycle dependent localization. Cell Motility Cytoskeleton. 1993;26:214–226. doi:10.1002/cm.970260305.
   PubMed Web of Science ®Google Scholar
• Liao H, Winkfein RJ, Mack G, Rattner JB, Yen TJ. CENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosis. J Cell Biol. 1995;130:507–518. doi:10.1083/jcb.130.3.507.
   PubMed Web of Science ®Google Scholar
• Dai Y, Liu L, Zeng T, Zhu YH, Li J, Chen L, Li Y, Yuan Y-F, Ma S, Guan X-Y, et al. Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma. Biochem Biophys Res Commun. 2013;436:711–718. doi:10.1016/j.bbrc.2013.06.021.
   PubMed Web of Science ®Google Scholar
• Kim HE, Kim DG, Lee KJ, Son JG, Song MY, Park YM, Kim -J-J, Cho S-W, Chi S-G, Cheong HS, et al. Frequent amplification of CENPF, GMNN and CDK13 genes in hepatocellular carcinomas. PLoS One. 2012;7:e43223. doi:10.1371/journal.pone.0043223.
   PubMed Web of Science ®Google Scholar
• Brendle A, Brandt A, Johansson R, Enquist K, Hallmans G, Hemminki K, Lenner P, Försti A. Single nucleotide polymorphisms in chromosomal instability genes and risk and clinical outcome of breast cancer: a Swedish prospective case-control study. Eur J Cancer. 2009;45:435–442. doi:10.1016/j.ejca.2008.10.001.
   PubMed Web of Science ®Google Scholar
• Chen WB, Cheng XB, Ding W, Wang YJ, Chen D, Wang JH, Fei R-S. Centromere protein F and survivin are associated with high risk and a poor prognosis in colorectal gastrointestinal stromal tumours. J Clin Pathol. 2011;64:751–755. doi:10.1136/jcp.2011.089631.
   PubMed Web of Science ®Google Scholar
• Sun JB, Huang JZ, Lan J, Zhou K, Gao Y, Song ZG, Deng Y, Liu L, Dong Y, Liu X, et al. Overexpression of CENPF correlates with poor prognosis and tumor bone metastasis in breast cancer. Cancer Cell Int. 2019;19:264. doi:10.1186/s12935-019-0986-8.
   PubMed Web of Science ®Google Scholar
• Herrera-Esparza R, Herrera-van-Oostdam D, López-Robles E, Avalos-Díaz E. The role of apoptosis in autoantibody production. Reumatismo. 2007;59:87–99.
   PubMedGoogle Scholar
• Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med. 1994;179:1317–1330. doi:10.1084/jem.179.4.1317.
   PubMed Web of Science ®Google Scholar
• Frisoni L, McPhie L, Colonna L, Sriram U, Monestier M, Gallucci S, Caricchio R. Nuclear autoantigen translocation and autoantibody opsonization lead to increased dendritic cell phagocytosis and presentation of nuclear antigens: a novel pathogenic pathway for autoimmunity? J Immunol. 2005;175:2692–2701. doi:10.4049/jimmunol.175.4.2692.
   PubMed Web of Science ®Google Scholar
• Fransen JH, Hilbrands LB, Ruben J, Stoffels M, Adema GJ, van der Vlag J, Berden JH. Mouse dendritic cells matured by ingestion of apoptotic blebs induce T cells to produce interleukin-17. Arthritis Rheum. 2009;60:2304–2313. doi:10.1002/art.24719.
   PubMed Web of Science ®Google Scholar
• Racanelli V, Prete M, Musaraj G, Dammacco F, Perosa F. Autoantibodies to intracellular antigens: generation and pathogenetic role. Autoimmun Rev. 2011;10:503–508. doi:10.1016/j.autrev.2011.03.001.
   PubMed Web of Science ®Google Scholar
• Mevorach D, Zhou JL, Song X, Elkon KB. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med. 1998;188:387–392. doi:10.1084/jem.188.2.387.
   PubMed Web of Science ®Google Scholar
• Hansen MH, Nielsen HV, Ditzel HJ. Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells. J Immunol. 2002;169:2701–2711. doi:10.4049/jimmunol.169.5.2701.
   PubMed Web of Science ®Google Scholar
• Fernández Madrid F. Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. Cancer Lett. 2005;230:187–198. doi:10.1016/j.canlet.2004.12.017.
   PubMed Web of Science ®Google Scholar
• Macdonald IK, Parsy-Kowalska CB, Chapman CJ. Autoantibodies: opportunities for early cancer detection. Trends Cancer. 2017;3:198–213. doi:10.1016/j.trecan.2017.02.003.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang J, Wang S, Pang Z, Wang Z, Zhou W, Wu M. Screening of autoantibodies as potential biomarkers for hepatocellular carcinoma by using T7 phase display system. Cancer Epidemiol. 2012;36:82–88. doi:10.1016/j.canep.2011.04.001.
   PubMed Web of Science ®Google Scholar
• Cappello F, Angileri F, de Macario EC, Macario AJ. Chaperonopathies and chaperonotherapy. Hsp60 as therapeutic target in cancer: potential benefits and risks. Curr Pharm Des. 2013;19:452–457. doi:10.2174/138161213804143653.
   PubMed Web of Science ®Google Scholar
• Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res. 2005;4:1123–1133. doi:10.1021/pr0500814.
   PubMed Web of Science ®Google Scholar
• Ersvaer E, Zhang JY, McCormack E, Olsnes A, Anensen N, Tan EM, Gjertsen BT, Bruserud Ø. Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. Eur J Haematol. 2007;79:210–225. doi:10.1111/j.1600-0609.2007.00899.x.
   PubMed Web of Science ®Google Scholar
• Li YM, Zhu Z, Zhang SH, Yu DH, Yu HY, Liu LN, Cao X, Wang L, Gao H, Zhu M, et al. ShRNA-targeted centromere protein A inhibits hepatocellular carcinoma growth. PLoS One. 2011;6:e17794. doi:10.1371/journal.pone.0017794.
   PubMed Web of Science ®Google Scholar
• Tomonaga T, Matsushita K, Yamaguchi S, Oohashi T, Shimada H, Ochiai T, Yoda K, Nomura F. Overexpression and mistargeting of centromere protein-A in human primary colorectal cancer. Cancer Res. 2003;63:3511–3516.
   PubMed Web of Science ®Google Scholar
• Perosa F, Prete M, Di Lernia G, Ostuni C, Favoino E, Valentini G. Anti-centromere protein A antibodies in systemic sclerosis: significance and origin. Autoimmun Rev. 2016;15:102–109. doi:10.1016/j.autrev.2015.10.001.
   PubMed Web of Science ®Google Scholar
• Suber T, Rosen A. Apoptotic cell blebs: repositories of autoantigens and contributors to immune context. Arthritis Rheum. 2009;60:2216–2219. doi:10.1002/art.24715.
   PubMed Web of Science ®Google Scholar
• Savill J, Fadok V, Henson P, Haslett C. Phagocyte recognition of cells undergoing apoptosis. Immunol Today. 1993;14:131–136. doi:10.1016/0167-5699(93)90215-7.
   PubMedGoogle Scholar
• Ohlsson M, Jonsson R, Brokstad KA. Subcellular redistribution and surface exposure of the Ro52, Ro60 and La48 autoantigens during apoptosis in human ductal epithelial cells: a possible mechanism in the pathogenesis of Sjögren’s syndrome. Scand J Immunol. 2002;56:456–469. doi:10.1046/j.1365-3083.2002.01072_79.x.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Kawakami A, Eguchi K. Mechanisms of autoantibody production and the relationship between autoantibodies and the clinical manifestations in Sjogren’s syndrome. Transl Res. 2006;148:281–288. doi:10.1016/j.trsl.2006.07.003.
   PubMed Web of Science ®Google Scholar
• Grimsley C, Ravichandran KS. Cues for apoptotic cell engulfment: eat-me, don’t eat-me and come-get-me signals. Trends Cell Biol. 2003;13:648–656. doi:10.1016/j.tcb.2003.10.004.
   PubMed Web of Science ®Google Scholar
• Gardai SJ, Bratton DL, Ogden CA, Henson PM. Recognition ligands on apoptotic cells: a perspective. J Leukoc Biol. 2006;79:896–903. doi:10.1189/jlb.1005550.
   PubMed Web of Science ®Google Scholar
• Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;392:86–89. doi:10.1038/32183.
   PubMed Web of Science ®Google Scholar
• Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med. 1999;5:1249–1255. doi:10.1038/15200.
   PubMed Web of Science ®Google Scholar